Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children3710.24287/1726-1708-2018-17-1-117-132СтатьиApplication of flow systems in laboratory diagnostics for the integral evaluation of the hemostatic systemПрименение проточных систем в лабораторной диагностике для интегральной оценки системы гемостазаUshakovaO. E.УшаковаО.Е.
Russian Federation
NechipurenkoD. Y.НечипуренкоД.Ю.
Russian Federation
ButylinA. A.БутылинА. А.
Russian Federation
https://orcid.org/0000-0002-8128-7757PanteleevM. A.ПантелеевМ.А.
Russian Federation

PhD, DSc, Head of the Laboratory of cellular hemostasis and trombosis

Russia 117997, Moscow, Samory Mashela st., 1

mapanteleev@yandex.ruI.M. Sechenov First Moscow State Medical University (Sechenov University) Center for Theoretical Problems of Physicochemical Pharmacology Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, ImmunologyФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России, ФГБУН «Центр теоретических проблем физико-химической фармакологии» РАН, ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава РоссииCenter for Theoretical Problems of Physicochemical Pharmacology Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Faculty of Physics, Moscow State UniversityФГБУН «Центр теоретических проблем физико-химической фармакологии» РАН, ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России, ФГБОУ ВО «Московский государственный университет им. М.В. Ломоносова»Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Faculty of Physics, Moscow State UniversityФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России, ФГБОУ ВО «Московский государственный университет им. М.В. Ломоносова»Center for Theoretical Problems of Physicochemical Pharmacology Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Faculty of Physics, Moscow State University Moscow Institute of Physics and Technology (State University)ФГБУН «Центр теоретических проблем физико-химической фармакологии» РАН, ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России, ФГБОУ ВО «Московский государственный университет им. М.В. Ломоносова», ФГАОУ ВО «Московский физико-технический институт (государственный университет)»0902201817111713209082018Copyright ©; 2018, «D. Rogachev NMRCPHOI»Copyright ©; 2018, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2018«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/37

The assessment of thrombosis and bleeding risks is one of the most important tasks of laboratory diagnostics of disorders in the hemostasis system. For this purpose the highly specialized tests are not always appropriate, because these assays are focused on specific markers or pathologies of individual links: the level of coagulation factors, the level of D-dimers, ADP- and serotonininduced platelet activation, effects of acetyl salicylic acid on aggregation. Nowadays, integral assays are the most promising approach, simulating hemostatic process in vivo – thromboelastography, thrombodynamics, thrombin generation. These tests are designed to specify the risk of thrombosis or bleeding with co-origin, as well as screening and monitoring of drug therapy. One of the approaches in the development of integral assays are flow systems where plasma or whole blood flow is formed over the hemostatic activator, and the growth of the thrombus is recorded on the video. There are commercially available samples of such devices, and some experience of its application in clinic. However, there are no uniform standards and clinical guidelines. This review describes examples of flow chambers exploitation for diagnosis, existing problems of its usage and the opportunities that it can provide to the clinicians.

integral assays of hemostasismicrofluidicsfunctional assaysthrombosisинтегральные тесты гемостазамикрофлюидикафункциональные тестытромбозПолохов Д.М., Пантелеев М.А. Сов-ременные подходы в лабораторной диагностике тромбоцитарного гемостаза. Hematology. Transfusiology. Eastern Europe 2016; 2: 270-90.Shen F., Kastrup C.J., Liu Y., Ismagilov R.F. Threshold response of initiation of blood coagulation by tissue factor in patterned microfluidic capillaries is controlled by shear rate. Arterioscler Thromb Vasc Biol 2008; 28: 2035-41.Andree H.A., Contino P.B., Repke D., Gentry R., Nemerson Y. Transport rate limited catalysis on macroscopic surfaces: the activation of factor X in a continuous flow enzyme reactor. Biochemistry 1994; 33: 4368-74.Katoh S., Matsubara I., Sada E. Effect of shear rate on activation rate of factor X. Ann Biomed Eng 1978; 6: 60-7.Ilkan Z., Wright J.R., Goodall A.H., Gibbins J.M., Jones C.I., MahautSmith M.P. Evidence for shear-mediated Ca2+ entry through mechanosensitive cation channels in human platelets and a megakaryocytic cell line. J Biol Chem 2017; 292: 9204-17.Ruggeri Z.M., Orje J.N., Habermann R., Federici A.B., Reininger A.J. Activation-independent platelet adhesion and aggregation under elevated shear stress. Blood 2006; 108: 1903-10.Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001; 138: 152-63.Ito M., Kaikita K., Sueta D., Ishii M., Oimatsu Y., Arima Y., Iwashita S., et al. Total Thrombus-Formation Ana-lysis System (T-TAS) Can Predict Periprocedural Bleeding Events in Patients Undergoing Catheter Ablation for Atrial Fibrillation. J Am Heart Assoc 2016; 5.Ruggeri Z.M. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Best Pract Res Clin Haematol 2001; 14: 257-79.Qiu Y., Ciciliano J., Myers D.R., Tran R., Lam W.A. Platelets and physics: How platelets "feel" and respond to their mechanical microenvironment. Blood Rev 2015; 29: 377-86.Siedlecki C.A., Lestini B.J., Kottke-Marchant K.K., Eppell S.J., Wilson D.L., Marchant R.E. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 1996; 88: 2939-50.Stockschlaeder M., Schneppenheim R., Budde U. Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis. Blood Coagul Fibrinolysis 2014; 25: 206-16.Jackson S.P. The growing complexity of platelet aggregation. Blood 2007; 109: 5087-95.Gale A.J. Continuing education course #2: current understanding of hemostasis. Toxicol Pathol 2011; 39: 273-80.Kauskot A., Hoylaerts M.F. Platelet receptors. Handb Exp Pharmacol 2012; 23-57.Thon J.N., Italiano J.E. Platelets: produ-ction, morphology and ultrastructure. Handb Exp Pharmacol 2012; 3-22.Пантелеев М.А., Атауллаханов Ф.И. Свер-тывание крови: биохимические основы. Клиническаяонкогематология 2008; 1: 50-62.Vadivel K., Bajaj S.P. Structural biology of factor VIIa/tissue factor initiated coagulation. Front Biosci (Landmark Ed) 2012; 17: 2476-94.Renne T., Schmaier A.H., Nickel K.F., Blomback M., Maas C. In vivo roles of factor XII. Blood 2012; 120: 4296-303.Пантелеев М.А., Атауллаханов Ф.И. Свертывание крови: методы исследования и механизмы регуляции (часть 2). Клиническая онкогематология 2008; 1: 174-81.Stalker T.J., Newman D.K., Ma P., Wannemacher K.M., Brass L.F. Platelet signaling. Handb Exp Pharmacol 2012;59-85.Lopez J.A., Andrews R.K., Afshar-Kharghan V., Berndt M.C. Bernard-Soulier syndrome. Blood 1998; 91: 4397-418.Воробьёв А.И. Руководство по гематологии в 3-х тт. - М.: Изд. "Нью-диамед" 2002.Lipets E.A.F. Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk. Thrombosis journal 2015; 13: 15.Lawson C.A., Yan S.D., Yan S.F., Liao H., Zhou Y.S., Sobel J., Kisiel W., et al. Monocytes and tissue factor promote thrombosis in a murine model of oxygen deprivation. J Clin Invest 1997; 99: 1729-38.de Groot P.G., Urbanus R.T., Roest M. Platelet interaction with the vessel wall. Handb Exp Pharmacol 2012; 87-110.Paniccia R., Priora R., Liotta A.A., Abbate R. Platelet function tests: a com-parative review. Vasc Health Risk Manag 2015; 11: 133-48.Lippi G., Favaloro E.J., Salvagno G.L., Franchini M. Laboratory assessment and perioperative management of patients on antiplatelet therapy: from the bench to the bedside. Clin Chim Acta 2009; 405: 8-16.Haas T., Spielmann N., Mauch J., Madj-dpour C., Speer O., Schmugge M., Weiss M. Comparison of throm-boelastometry (ROTEM(R)) with stan-dard plasmatic coagulation testing in paediatric surgery. Br J Anaesth 2012; 108: 36-41.Cuker A., Siegal D.M., Crowther M.A., Garcia D.A. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 2014; 64: 1128-39.Липец Е.Н., Атауллаханов Ф.И., Панте-леев М.А. Интегральные лабораторные тесты гемостаза в диагностике гиперкоагуляции и оценке риска тромбоза. Онкогематология 2015; 10: 73-91.Lance M.D. A general review of major global coagulation assays: thrombelastography, thrombin generation test and clot waveform analysis. Thromb J 2015; 13: 1.Kyrle P.A., Mannhalter C., Beguin S., Stumpflen A., Hirschl M., Weltermann A., et al. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol 1998; 18: 1287-91.Dashkevich N.M., Ovanesov M.V., Balan-dina A.N., Karamzin S.S., Shestakov P.I., Soshitova N.P., Tokarev A.A., et al. Thrombin activity propagates in space during blood coagulation as an excitation wave. Biophys J 2012; 103: 2233-40.Dashkevich N.M., Vuimo T.A., Ovsepyan R.A., Surov S.S., Soshitova N.P., Panteleev M.A., Ataullakhanov F.I., et al. Effect of pre-analytical conditions on the thrombodynamics assay. Thromb Res 2014; 133: 472-6.Lipets E., Vlasova O., Urnova E., Margolin O., Soloveva A., Ostapushchenko O., Andersen J., et al. Circulating contact-pathway-activating microparticles to-gether with factors IXa and XIa induce spontaneous clotting in plasma of hematology and cardiologic patients. PLoS One 2014, 9: e87692.Ovanesov M.V., Panteleev M.A., Sinau-ridze E.I., Kireev D.A., Plyushch O.P., Kopylov K.G., Lopatina E.G., et al. Mechanisms of action of recombinant activated factor VII in the context of tissue factor concentration and distribution. Blood Coagul Fibrinolysis 2008; 19: 743-55.Panteleev M.A., Dashkevich N.M., Atau-llakhanov F.I. Hemostasis and thrombosis beyond biochemistry: roles of geometry, flow and diffusion. Thromb Res 2015; 136: 699-711.Panteleev M.A., Ovanesov M.V., Kire-ev D.A., Shibeko A.M., Sinauridze E.I., Ananyeva N.M., Butylin A.A., et al. Spatial propagation and localization of blood coagulation are regulated by intrinsic and protein C pathways, respectively. Biophys J 2006; 90: 1489-500.Parunov L.A., Fadeeva O.A., Balandina A.N., Soshitova N.P., Kopylov K.G., Kumskova M.A., Gilbert J.C., et al. Improvement of spatial fibrin formation by the anti-TFPI aptamer BAX499: changing clot size by targeting extrinsic pathway initiation. J Thromb Haemost 2011; 9: 1825-34.Sinauridze E.I., Kireev D.A., Popenko N.Y., Pichugin A.V., Panteleev M.A., Krymskaya O.V., Ataullakhanov F.I. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 2007; 97: 425-34.Soshitova N.P., Karamzin S.S., Balandina A.N., Fadeeva O.A., Kretchetova A.V., Galstian G.M., Panteleev M.A., et al. Predicting prothrombotic tenden-cies in sepsis using spatial clot growth dynamics. Blood Coagul Fibrinolysis 2012; 23: 498-507.Solomon C., Asmis L.M., Spahn D.R. Is viscoelastic coagulation monitoring with ROTEM or TEG validated? Scand J Clin Lab Invest 2016; 76: 503-7.Duarte R.C.F., Ferreira C.N., Rios D.R.A., Reis H.J.D., Carvalho M.D.G. Thrombin generation assays for global evaluation of the hemostatic system: perspectives and limitations. Rev Bras Hematol Hemoter 2017; 39: 259-65.Panteleev M.A., Hemker H.C. Global/inte-gral assays in hemostasis diagnostics: promises, successes, problems and prospects. Thromb J 2015; 13: 5.Prabhakarpandian B., Shen M.C., Pant K., Kiani M.F. Microfluidic devices for modeling cell-cell and particle-cell interactions in the microvasculature. Microvasc Res 2011; 82: 210-20.Lawrence M.B., McIntire L.V., Eskin S.G. Effect of flow on polymorphonuclear leukocyte/endothelial cell adhesion. Blood 1987; 70: 1284-90.Schaff U., Mattila P.E., Simon S.I., Walcheck B. Neutrophil adhesion to E-selectin under shear promotes the redistribution and co-clustering of ADAM17 and its proteolytic substrate L-selectin. J Leukoc Biol 2008; 83: 99-105.Runyon M.K., Johnson-Kerner B.L., Isma-gilov R.F. Minimal functional model of hemostasis in a biomimetic microfluidic system. Angew Chem Int Ed Engl 2004; 43: 1531-6.Neeves K.B., Onasoga A.A., Wufsus A.R. The use of microfluidics in hemostasis: clinical diagnostics and biomimetic models of vascular injury. Curr Opin Hematol 2013; 20: 417-23.Prabhakarpandian B., Pant K., Scott R.C., Pattillo C.B., Irimia D., Kiani M.F., Sundaram S. Synthetic microvascular networks for quantitative analysis of particle adhesion. Biomed Microdevices 2008; 10: 585-95.Isenberg B.C., Williams C., Tranquillo R.T. Endothelialization and flow conditioning of fibrin-based media-equivalents. Ann Biomed Eng 2006; 34: 971-85.Rosano J.M., Tousi N., Scott R.C., Kryn-ska B., Rizzo V., Prabhakarpandian B., Pant K., et al. A physiologically realistic in vitro model of microvascular networks. Biomed Microdevices 2009; 11: 1051-7.Koning A.J., Lum P.Y., Williams J.M., Wright R. DiOC6 staining reveals organelle structure and dynamics in living yeast cells. Cell Motil Cytoskeleton 1993; 25: 111-28.van Kruchten R., Cosemans J.M., Heemskerk J.W. Measurement of whole blood thrombus formation using parallel-plate flow chambers - a practical guide. Platelets 2012; 23: 229-42.Neeves K.B., Maloney S.F., Fong K.P.,Schmaier A.A., Kahn M.L., Brass L.F., Diamond S.L. Microfluidic focal throm-bosis model for measuring murine platelet deposition and stability: PAR4 signaling enhances shear-resistance of platelet aggregates. J Thromb Haemost 2008; 6: 2193-201.Harrison P. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol 2005; 130: 3-10.Favaloro E.J. Clinical utility of the PFA-100. Semin Thromb Hemost 2008; 34: 709-33.Poon M.C., d'Oiron R., Hann I., Negrier C., de Lumley L., Thomas A., Karafoulidou A., et al. Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia. Semin Hematol 2001; 38: 21-5.Lippi G., Ippolito L., Zobbi V., Sandei F., Favaloro E.J. Sample collection and platelet function testing: influence of vacuum or aspiration principle on PFA-100 test results. Blood Coagul Fibrinolysis 2013; 24: 666-9.